EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dexmedetomidine alleviates renal ischemia reperfusion injury via suppressing SLC2A1-mediated glycolysis

Wei Ding, Lifang Xie, Lulu Wang, Wenli Huang, Yifei Dong, Quanlong Fang, Bingqian Fan, Tianxiang Yuan, Su Hu, Jingxing Hu, Ye Xiao, Kang Peng und 2 weitere

Biochemical Pharmacology · 2025

DOI: 10.1016/j.bcp.2025.117166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2025. Verfasst von Wei Ding und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The Second Affiliated Hospital of Anhui Medical University, Hefei City, Anhui Province 230601, China; Key Laboratory of…. Hauptthemen laut MEDLINE: Dexmedetomidine, Reperfusion Injury, Glycolysis, Glucose Transporter Type 1. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anhui Medical University, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal ischemia reperfusion injury (IRI) represents a significant factor in perioperative acute kidney injury (AKI), which in turn predisposes to acute renal failure. Dexmedetomidine (Dex) is an anesthetic drug with sedative and analgesic effects, and clinical evidence supports its renoprotective properties. However, the exact molecular mechanism of Dex's renoprotection remains unclear. Our research specifically focuses on the role of Dex in glycolysis mediated by solute carrier family 2 member 1 (SLC2A1). Here, the renal ischemia/reperfusion (I/R) mouse model and HK-2 oxygen-glucose deprivation/reoxygenation (OGD/R) cell model were established. Pharmacologically, the results showed that Dex ameliorated the injury induced by I/R and OGD/R. Mechanistically, renal IRI elevated SLC2A1 expression, whereas Dex decreased it. STF-31, an inhibitor of SLC2A1, attenuated renal IRI and inhibited glycolysis. Dex inhibited renal IRI in the presence of SLC2A1 but not in the absence. In vitro experiments similarly found this phenomenon. Additionally, Dex promoted SLC2A1 internalization followed by autophagic-lysosomal degradation, as evidenced by immunofluorescence staining and Western blot. In conclusion, Dex has been demonstrated to attenuate renal IRI by inhibiting SLC2A1-mediated glycolysis, which was regulated by SLC2A1 expression, internalization, and lysosomal degradation. The present study presents a novel mechanism by which Dex attenuates renal IRI from a metabolic perspective.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexmedetomidineReperfusion InjuryGlycolysisGlucose Transporter Type 1KidneyAnimalsMiceMaleMice, Inbred C57BLHumansCell LineAcute Kidney Injury

Stichwörter der Autor:innen

DexmedetomidineGlycolysisOxygen glucose deprivation/reoxygenationRenal ischemia/ reperfusion injuryRenal tubularSolute carrier family 2 member 1

Substanzen

DexmedetomidineGlucose Transporter Type 1Slc2a1 protein, mouse

Autor:innen und Institutionen

  • Department of Anesthesiology, The Second Affiliated Hospital of Anhui Medical University, Hefei City, Anhui Province 230601, China; Key Laboratory of Anesthesiology and Perioperative Medicine of Anhui Higher Education I…

Förderung

  • Anhui Medical University
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Ding, W., Xie, L., Wang, L., Huang, W., Dong, Y., Fang, Q., Fan, B., Yuan, T., Hu, S., Hu, J., Xiao, Y., Peng, K., Tao, W., & Hu, X. (2025). Dexmedetomidine alleviates renal ischemia reperfusion injury via suppressing SLC2A1-mediated glycolysis. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2025.117166

Vancouver

Ding W, Xie L, Wang L, Huang W, Dong Y, Fang Q, et al. Dexmedetomidine alleviates renal ischemia reperfusion injury via suppressing SLC2A1-mediated glycolysis. Biochemical Pharmacology. 2025. doi:10.1016/j.bcp.2025.117166

BibTeX
@article{Ding2025,
  author = {Ding, Wei and Xie, Lifang and Wang, Lulu and Huang, Wenli and Dong, Yifei and Fang, Quanlong and Fan, Bingqian and Yuan, Tianxiang and Hu, Su and Hu, Jingxing and Xiao, Ye and Peng, Kang and Tao, Wenhui and Hu, Xianwen},
  title = {Dexmedetomidine alleviates renal ischemia reperfusion injury via suppressing SLC2A1-mediated glycolysis},
  journal = {Biochemical Pharmacology},
  year = {2025},
  doi = {10.1016/j.bcp.2025.117166}
}
Kostenlos starten →